Table 1. Findings for CD4+, CD8+, CD4+/CD8+ ratio, NK cells variations in severe/critical COVID-19 disease compared to mild/moderate disease.
|
First Author (Country)
(Reference number) |
Sample size (N) |
Total lymphocytes
(P-value) |
T cells
(P-value) |
CD4+ cells
(P-value) |
CD8+ cells
(P-value) |
CD4+/CD8+ ratio
(P-value) |
NK cells
(P-value) |
B cells
(P-value) |
|---|---|---|---|---|---|---|---|---|
| Huang et al. (USA) (26) |
3017 | decreased (< 0.001) |
n.a. | decreased (< 0.001) |
decreased (< 0.001) |
n.a. | decreased (< 0.001) |
decreased (< 0.001) |
| Diao et al. (China) (27) |
522 | n.a. | decreased (< 0.01) |
decreased (< 0.01) |
decreased (< 0.01) |
n.a. | n.a. | n.a. |
| Wang et al. (China) (28) |
60 | decreased (< 0.001) |
n.a. | decreased (0.024) |
decreased (0.005) |
no difference (0.392) |
no difference (0.177) |
decreased (0.018) |
| Zheng et al. (China) (29) |
68 | n.a. | decreased (< 0.05) |
n.a | decreased (< 0.05) |
n.a | decreased (< 0.05) |
n.a. |
| n.a. – not available. NK – Natural killer cell. COVID-19 – coronavirus disease 2019. | ||||||||